| Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study JS Abramson, ML Palomba, LI Gordon, MA Lunning, M Wang, J Arnason, ... The Lancet 396 (10254), 839-852, 2020 | 2032 | 2020 |
| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 1039 | 2018 |
| Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed … M Kamdar, SR Solomon, J Arnason, PB Johnston, B Glass, V Bachanova, ... The Lancet 399 (10343), 2294-2308, 2022 | 590 | 2022 |
| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 562 | 2014 |
| B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large … M Snuderl, OK Kolman, YB Chen, JJ Hsu, AM Ackerman, P Dal Cin, ... The American journal of surgical pathology 34 (3), 327-340, 2010 | 485 | 2010 |
| Non-Hodgkin’s lymphomas AD Zelenetz, JS Abramson, RH Advani, CB Andreadis, JC Byrd, ... Journal of the National Comprehensive Cancer Network 8 (3), 288-334, 2010 | 456 | 2010 |
| Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303 NL Bartlett, WH Wilson, SH Jung, ED Hsi, MJ Maurer, LD Pederson, ... Journal of clinical oncology 37 (21), 1790-1799, 2019 | 417 | 2019 |
| The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma P Juszczynski, J Ouyang, S Monti, SJ Rodig, K Takeyama, J Abramson, ... Proceedings of the National Academy of Sciences 104 (32), 13134-13139, 2007 | 405 | 2007 |
| International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, ... Annals of Oncology 28 (7), 1436-1447, 2017 | 379 | 2017 |
| Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity BL Lampson, SN Kasar, TR Matos, EA Morgan, L Rassenti, MS Davids, ... Blood, The Journal of the American Society of Hematology 128 (2), 195-203, 2016 | 340 | 2016 |
| Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T) RM Alvi, MJ Frigault, MG Fradley, MD Jain, SS Mahmood, M Awadalla, ... Journal of the American College of Cardiology 74 (25), 3099-3108, 2019 | 311 | 2019 |
| Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity CA Jacobson, BD Hunter, R Redd, SJ Rodig, PH Chen, K Wright, ... Journal of Clinical Oncology 38 (27), 3095-3106, 2020 | 306 | 2020 |
| Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells P Karschnia, JT Jordan, DA Forst, IC Arrillaga-Romany, TT Batchelor, ... Blood, The Journal of the American Society of Hematology 133 (20), 2212-2221, 2019 | 302 | 2019 |
| Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma JS Abramson, M Hellmann, JA Barnes, P Hammerman, C Toomey, ... Cancer 116 (18), 4283-4290, 2010 | 284 | 2010 |
| Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach JS Abramson, MA Shipp Blood 106 (4), 1164-1174, 2005 | 283 | 2005 |
| Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma MJ Frigault, J Dietrich, M Martinez-Lage, M Leick, BD Choi, Z DeFilipp, ... Blood, The Journal of the American Society of Hematology 134 (11), 860-866, 2019 | 244 | 2019 |
| Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma BM Grande, DS Gerhard, A Jiang, NB Griner, JS Abramson, TB Alexander, ... Blood, The Journal of the American Society of Hematology 133 (12), 1313-1324, 2019 | 240 | 2019 |
| Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma SM Ansell, J Radford, JM Connors, M Długosz-Danecka, WS Kim, ... New England Journal of Medicine 387 (4), 310-320, 2022 | 236 | 2022 |
| Diagnosis and management of Castleman disease JD Soumerai, AR Sohani, JS Abramson Cancer control 21 (4), 266-278, 2014 | 222 | 2014 |
| Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC … K Dunleavy, MA Fanale, JS Abramson, A Noy, PF Caimi, S Pittaluga, ... The Lancet Haematology 5 (12), e609-e617, 2018 | 219 | 2018 |
